Drug Trial Radar · NCT02881086
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Last checked: Nov 20, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,023
Actual
Start
Aug 2016
Primary completion
Dec 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- Goethe UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 26, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase IV study with the primary goal to optimize therapy of adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma (LBL) by dose and time intensive, pediatric based chemotherapy, risk adapted stem cell transplantation (SCT) and minimal residual disease (MRD) based individualised and intensified therapy. Study will further evaluate the role of asparaginase intensification, the extended use of rituximab and the use of nelarabine as consolidation therapy in T-ALL in a phase III-part of the study. Furthermore two randomisations will focus on the role of central nervous system (CNS) irradiation in combination with intrathecal therapy versus intrathecal therapy only in B-precursor ALL/LBL and the role of SCT in high-risk patients with molecular complete remission. Finally a new, dose reduced induction therapy in combination with Imatinib will be evaluated in Ph/BCR-ABL positive ALL.
Conditions
- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
Interventions
RituximabDrug
NelarabineDrug
PEG-AsparaginaseDrug
Cranial irradiationProcedure
ImatinibDrug
IdarubicinDrug
DexamethasoneDrug
CyclophosphamideDrug
FludarabineDrug
VincristineDrug
MercaptopurineDrug
VP16Drug
Daunorubicin (DNR)Drug
MethotrexateDrug
Stem cell transplantationProcedure
CytarabineDrug
VindesineDrug
AdriamycinDrug
PrednisoloneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event free survivalTime frame: 3.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital of Frankfurt (Main)
Frankfurt am Main, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.